Loading
Lymphoma Diagnosis and Treatment / Chronic Lymphocytic Leukemia Research · Journal article
British Journal of Haematology · August 17, 2026
Well-designed and adequately powered for the question it asks.
This population-based cohort of 34,427 English CLL patients (2014–2022) demonstrates independent associations between socioeconomic deprivation, geographic region, and both incidence and survival outcomes. The most deprived quintile had higher CLL incidence (IRR 1.06) and worse overall survival (HR 1.42) and cause-specific survival (HR 1.28) compared to the least deprived, with marked regional variation in cause-specific survival (HR range 0.84–1.12 relative to London). These findings reveal previously unreported inequalities in CLL epidemiology and outcomes in England.
Retrospective population-based cohort study. All patients with chronic lymphocytic leukaemia diagnosed in England 2014–2022, identified from the national cancer registry.. Compared with: Within-cohort comparisons by socioeconomic quintile (most vs. least deprived) and government region (vs. London baseline). n = 34,427. England-wide; 9 government regions represented.
34,427 consecutive CLL diagnoses recorded 2014–2022; largest European dataset on record Incidence rate ratio 1.06 (95% CI 1.02–1.10) for most vs. least deprived quintile Incidence rate ratio fall of 0.70 (95% CI 0.67–0.73) for 2022 vs. 2014
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should be aware that CLL incidence and survival outcomes vary significantly by socioeconomic status and geographic region in England, suggesting unequal access to care, treatment, or prognostic factors. These disparities warrant investigation into causative factors and targeted interventions to improve equity in CLL management.
Large national cohort study with 34,427 consecutive CLL diagnoses, multivariable analysis adjusting for key confounders, and hard clinical endpoints (overall and cause-specific survival) demonstrating previously unreported socioeconomic and geographic disparities.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should be aware that CLL incidence and survival outcomes vary significantly by socioeconomic status and geographic region in England, suggesting unequal access to care, treatment, or prognostic factors. These disparities warrant investigation into causative factors and targeted interventions to improve equity in CLL management.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Summary To re‐evaluate chronic lymphocytic leukaemia (CLL) epidemiology in the era of modern therapy, data were extracted from the English National Cancer Registration Dataset (NCRD). A total of 34 427 consecutive diagnoses of CLL were recorded (2014–2022), the largest European dataset on record. In addition to known associations with age, gender‐ethnicity, multivariable analysis showed incidence rate ratio (IRR) variations with government region (IRR ranging from 0.78 to 0.94 vs. London), socioeconomic deprivation (1.06 [95% confidence interval (CI) 1.02–1.10] for most vs. least deprived quintile) and IRR fall in successive calendar years (0.70 [95% CI 0.67–0.73] for 2022 vs. 2014). With a median follow‐up of 74.4 months, 36.9% of patients had died, including 13.6% from blood cancer. 1‐, 3‐ and 5‐year overall survival (OS)/net survival rates were 90%/94%, 78%/87% and 67%/81%, respectively. Age, male gender, comorbidity and socioeconomic deprivation were independently associated with shorter OS and cause‐specific survival (CSS), with OS‐hazard ratio (HR) of 1.42 (95% CI 1.34–1.50) and CSS‐HR of 1.28 (1.16–1.41) for the most versus least deprived quintiles. In addition, government region was independently associated with CSS, with HRs relative to London ranging from 0.84 (0.74–0.96) to 1.12 (0.99–1.27). Our findings reveal previously unreported disparities in CLL incidence and survival based on place of residence.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.